<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Precigen Inc — News on 6ix</title>
<link>https://6ix.com/company/precigen-inc</link>
<description>Latest news and press releases for Precigen Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/precigen-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835abe078dffbe2df10dc2c.webp</url>
<title>Precigen Inc</title>
<link>https://6ix.com/company/precigen-inc</link>
</image>
<item>
<title>Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-to-participate-in-a-fireside-chat-with-hc-wainwright-on-march-31</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-to-participate-in-a-fireside-chat-with-hc-wainwright-on-march-31</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of</description>
</item>
<item>
<title>Precigen Reports Full Year 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-reports-full-year-2025-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-reports-full-year-2025-financial-results-and-business-updates</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS™ (zopapogene imadenovec-drba), the first-and-only FDA-approved treatment</description>
</item>
<item>
<title>Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-to-announce-full-year-2025-financial-results-and-provide-business-updates-on-march-25-33</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-to-announce-full-year-2025-financial-results-and-provide-business-updates-on-march-25-33</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., March 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of</description>
</item>
<item>
<title>New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis</title>
<link>https://6ix.com/company/precigen-inc/news/expert-consensus-published-laryngoscope-recommends-130500265</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/expert-consensus-published-laryngoscope-recommends-130500265</guid>
<pubDate>Tue, 20 Jan 2026 13:05:00 GMT</pubDate>
<description>Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the publication of a new expert consensus paper sponsored by the Recurrent Respiratory Papillomatosis Foundation (RRPF) and authored by 16 leading physicians in the field of recurrent respiratory papillomatosis (RRP) has been published in The Laryngoscope, one of the field's most respected peer-reviewed jou</description>
</item>
<item>
<title>Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-showcases-rapid-commercialization-momentum-and-growing-market-adoption-first</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-showcases-rapid-commercialization-momentum-and-growing-market-adoption-first</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS in August 2025, the first-and-only FDA-approved treatment for adults</description>
</item>
<item>
<title>Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., Jan. 5, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, today</description>
</item>
<item>
<title>Precigen Reports Third Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-reports-third-quarter-2025-financial-results-and-business-updates-2025-11-13</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-reports-third-quarter-2025-financial-results-and-business-updates-2025-11-13</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>PAPZIMEOS (zopapogene imadenovec-drba) received full approval by the FDA in August PAPZIMEOS launched with a broad label in the US as the first and only</description>
</item>
<item>
<title>Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-announce-third-quarter-2025-financial-results-and-provide-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-announce-third-quarter-2025-financial-results-and-provide-business-updates</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., Nov. 6, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative</description>
</item>
<item>
<title>Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-announces-long-term-follow-results-highlighting-ongoing-durable-complete</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-announces-long-term-follow-results-highlighting-ongoing-durable-complete</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>15 out of 18 complete responders (83%) demonstrate continued complete response with median follow-up of 36 months Reduction in surgeries compared to year</description>
</item>
<item>
<title>EVERSANA Named by Precigen for U.S. Commercialization of PAPZIMEOS</title>
<link>https://6ix.com/company/precigen-inc/news/eversana-named-by-precigen-for-us-commercialization-of-papzimeos</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/eversana-named-by-precigen-for-us-commercialization-of-papzimeos</guid>
<pubDate>Thu, 11 Sep 2025 12:00:00 GMT</pubDate>
<description>EVERSANA, a leading provider of global commercialization services to the life sciences industry, has been named by Precigen, Inc. for commercialization of PAPZIMEOS™ (zopapogene imadenovec-drba), approved by the U.S. Food and Drug Administration on August 14, 2025.</description>
</item>
<item>
<title>Precigen Announces Up to $125 Million Non-Dilutive Financing</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-announces-125-million-non-dilutive-financing-2025-09-03</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-announces-125-million-non-dilutive-financing-2025-09-03</guid>
<pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
<description>$100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international</description>
</item>
<item>
<title>Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-participate-upcoming-virtual-fireside-chats-hosted-cantor-and-hc-wainwright</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-participate-upcoming-virtual-fireside-chats-hosted-cantor-and-hc-wainwright</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative</description>
</item>
<item>
<title>Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-announces-full-fda-approval-papzimeos-zopapogene-imadenovec-drba-first-and</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-announces-full-fda-approval-papzimeos-zopapogene-imadenovec-drba-first-and</guid>
<pubDate>Fri, 15 Aug 2025 04:00:00 GMT</pubDate>
<description>PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP</description>
</item>
<item>
<title>Precigen Reports First Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-reports-first-quarter-2025-financial-results-and-business-updates-2025-05-14</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-reports-first-quarter-2025-financial-results-and-business-updates-2025-05-14</guid>
<pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
<description>PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under</description>
</item>
<item>
<title>Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-and-recurrent-respiratory-papillomatosis-foundation-host-2025-international</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-and-recurrent-respiratory-papillomatosis-foundation-host-2025-international</guid>
<pubDate>Wed, 16 Apr 2025 04:00:00 GMT</pubDate>
<description>– International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory</description>
</item>
<item>
<title>Precigen Reports Full Year 2024 Financial Results and Business Updates</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-reports-full-year-2024-financial-results-and-business-updates-2025-03-19</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-reports-full-year-2024-financial-results-and-business-updates-2025-03-19</guid>
<pubDate>Wed, 19 Mar 2025 04:00:00 GMT</pubDate>
<description>FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action</description>
</item>
<item>
<title>Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-announce-full-year-2024-financial-results-and-provide-business-updates-march</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-announce-full-year-2024-financial-results-and-provide-business-updates-march</guid>
<pubDate>Thu, 13 Mar 2025 04:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene</description>
</item>
<item>
<title>FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025</title>
<link>https://6ix.com/company/precigen-inc/news/fda-grants-priority-review-precigens-bla-prgn-2012-treatment-adults-recurrent</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/fda-grants-priority-review-precigens-bla-prgn-2012-treatment-adults-recurrent</guid>
<pubDate>Tue, 25 Feb 2025 05:00:00 GMT</pubDate>
<description>– Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, would provide significant improvements in the</description>
</item>
<item>
<title>Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-present-plans-realizing-commercial-vision-prgn-2012-43rd-annual-jp-morgan</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-present-plans-realizing-commercial-vision-prgn-2012-43rd-annual-jp-morgan</guid>
<pubDate>Mon, 13 Jan 2025 05:00:00 GMT</pubDate>
<description>– PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease – – Company completed BLA</description>
</item>
<item>
<title>Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/precigen-inc/news/precigen-present-43rd-annual-jp-morgan-healthcare-conference-2025-01-09</link>
<guid isPermaLink="true">https://6ix.com/company/precigen-inc/news/precigen-present-43rd-annual-jp-morgan-healthcare-conference-2025-01-09</guid>
<pubDate>Thu, 09 Jan 2025 05:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., Jan. 9, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene</description>
</item>
</channel>
</rss>